Goldman Sachs’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-13,935
| Closed | -$23.4K | – | 5059 |
|
|
2024
Q3 | $23.4K | Buy |
13,935
+2,506
| +22% | +$4.21K | ﹤0.01% | 4697 |
|
|
2024
Q2 | $16.2K | Buy |
+11,429
| New | +$16.2K | ﹤0.01% | 4618 |
|
|
2023
Q3 | – | Sell |
-11,297
| Closed | -$29.7K | – | 4786 |
|
|
2023
Q2 | $29.7K | Sell |
11,297
-7,573
| -40% | -$19.9K | ﹤0.01% | 4718 |
|
|
2023
Q1 | $68.7K | Sell |
18,870
-38
| -0.2% | -$138 | ﹤0.01% | 4723 |
|
|
2022
Q4 | $74.5K | Sell |
18,908
-1,821
| -9% | -$7.17K | ﹤0.01% | 4731 |
|
|
2022
Q3 | $88K | Buy |
+20,729
| New | +$88K | ﹤0.01% | 4950 |
|
|
2022
Q2 | – | Sell |
-12,205
| Closed | -$68K | – | 5734 |
|
|
2022
Q1 | $68K | Buy |
+12,205
| New | +$68K | ﹤0.01% | 5407 |
|
|
2021
Q2 | – | Sell |
-12,986
| Closed | -$144K | – | 5399 |
|
|
2021
Q1 | $144K | Buy |
+12,986
| New | +$144K | ﹤0.01% | 4946 |
|